ArticleCureus2026
Mind and Muscle: A Retrospective Study on the Management of Psychiatric Comorbidities in Patients With Fibromyalgia Treated With Pregabalin Versus Milnacipran.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFibromyalgia syndrome is a debilitating chronic disease with symptoms of pain and fatigue that profoundly impact patients' quality of life. This disability can lead to the development of psychiatric comorbidities, causing a compounding decline in overall well-being. Pregabalin and milnacipran are options for patients seeking symptomatic relief, but we hypothesized that psychiatric outcomes differ between patients with fibromyalgia treated with milnacipran versus pregabalin.
methodsTriNetX, a de-identified healthcare organization (HCO) network, collected and analyzed the study data. Patients with fibromyalgia receiving either milnacipran or pregabalin without opioid analgesics were included in this study and separated based on their use of milnacipran or pregabalin. Risk difference, risk ratios, Kaplan-Meier analysis with log-rank tests (LRTs), hazard ratios, and proportionality were analyzed for differences among several conditions: somnolence, opioid use disorder (OUD), depressive episodes (DEs), and anxiety disorder (AD) between patients on milnacipran versus pregabalin.
resultsIn total, 119,406 patients met the eligibility criteria, and propensity score matching resulted in 6,726 patients in each cohort. Milnacipran decreased the risk of somnolence and OUD (somnolence: 0.942%, 95% confidence interval (CI): 0.0445-1.44%, p<0.001; OUD: 0.779%, 95% CI: 0.061-1.5%, p<0.0333) (DEs: 2.1%, 95% CI: 0.3-3.89%, p=0.217; AD: 1.18%, 95% CI: -0.623-2.99%, p=0.119). Kaplan-Meier analysis demonstrated the benefit of milnacipran in the management of somnolence. There is no difference in the management of anxiety. There was a trending improvement in OUD and DE with milnacipran, but it did not show clear superiority (LRT somnolence, p<0.001; OUD, p=0.0584; DE, p=0.0504; anxiety, p=0.441).
conclusionOverall, differences observed between groups may not be clinically significant. This information may help clinicians and patients employ well-informed, shared decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.